Transgene Statistics

Total Valuation

Transgene has a market cap or net worth of EUR 92.66 million. The enterprise value is 114.12 million.

Market Cap	92.66M
Enterprise Value	114.12M

Important Dates

The last earnings date was Thursday, November 7, 2024.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Transgene has 131.99 million shares outstanding. The number of shares has increased by 1.17% in one year.

Current Share Class	n/a
Shares Outstanding	131.99M
Shares Change (YoY)	+1.17%
Shares Change (QoQ)	-0.42%
Owned by Insiders (%)	70.04%
Owned by Institutions (%)	1.04%
Float	34.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.94
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.98
EV / Sales	17.57
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.94

Financial Position

The company has a current ratio of 1.57

Current Ratio	1.57
Quick Ratio	1.40
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.95
Interest Coverage	-46.46

Financial Efficiency

Return on equity (ROE) is -214.69% and return on invested capital (ROIC) is -54.54%.

Return on Equity (ROE)	-214.69%
Return on Assets (ROA)	-38.85%
Return on Capital (ROIC)	-54.54%
Revenue Per Employee	44,479
Profits Per Employee	-156,925
Employee Count	141
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.56% in the last 52 weeks. The beta is 0.73, so Transgene's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	-50.56%
50-Day Moving Average	0.83
200-Day Moving Average	1.07
Relative Strength Index (RSI)	34.44
Average Volume (20 Days)	27,171

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Transgene had revenue of EUR 6.49 million and -22.91 million in losses. Loss per share was -0.23.

Revenue	6.49M
Gross Profit	-22.95M
Operating Income	-31.17M
Pretax Income	-22.91M
Net Income	-22.91M
EBITDA	-30.04M
EBIT	-31.17M
Loss Per Share	-0.23

Full Income Statement

Balance Sheet

The company has 15.32 million in cash and 36.78 million in debt, giving a net cash position of -21.46 million or -0.16 per share.

Cash & Cash Equivalents	15.32M
Total Debt	36.78M
Net Cash	-21.46M
Net Cash Per Share	-0.16
Equity (Book Value)	-616,000
Book Value Per Share	-0.01
Working Capital	6.95M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -35.54 million and capital expenditures -3.27 million, giving a free cash flow of -38.81 million.

Operating Cash Flow	-35.54M
Capital Expenditures	-3.27M
Free Cash Flow	-38.81M
FCF Per Share	-0.29

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-480.04%
Pretax Margin	-352.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Transgene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.17%
Shareholder Yield	-1.17%
Earnings Yield	-32.26%
FCF Yield	-41.89%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Transgene has an Altman Z-Score of -3.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.44
Piotroski F-Score	n/a